Chiara Malinverni, Andrea Bernardelli, Ingrid Glimelius, Massimo Mirandola, Karin E Ekstrom Smedby, Maria Chiara Tisi, Eva Giné, Alexandra Albertsson-Lindblad, Ana Marin Marin-Niebla, Alice Di Rocco, Filipa Moita, Roberta Sciarra, Sandra Bašić-Kinda, Georg R Hess, Anke Ohler, Christian W Eskelund, Alessandro Re, Isacco Ferrarini, Arne Kolstad, Riikka Katariina Räty, Francesca Maria Quaglia, Toby A Eyre, Greta Scapinello, Piero Maria Stefani, Lucia Morello, Luca Nassi, Stefan Hohaus, Simone Ragaini, Vittorio Ruggero Zilioli, Riccardo Bruna, Federica Cocito, Annalisa Arcari, Mats Jerkeman, Carlo Visco
Patients with mantle cell lymphoma (MCL) who experience first relapse/refractoriness can be categorized into early or late progression-of-disease (POD) groups, with a threshold of 24 months from the initial MCL diagnosis. Bruton tyrosine kinase inhibitors (BTKi) are established standard treatment at first relapse, but their effectiveness as compared to chemoimmunotherapy (CIT) in late-POD patients remains unknown. In this international, observational cohort study, we evaluated outcomes amongst patients at first, late-POD beyond 24 months...
May 16, 2024: Blood